References
- Stokes E, Ye X, Shah M, et al. Impact of bleeding-related complications and/or blood product transfusions on hospital costs in inpatient surgical patients. BMC Health Serv Res. 2011;11:135.
- Boucher BA, Traub O. Achieving hemostasis in the surgical field. Pharmacotherapy. 2009;29:2S–7S.
- Levi M, Cromheecke ME, de Jonge E, et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet. 1999;354(9194):1940–1947.
- De la Torre RA, Bachman SL, Wheeler AA, et al. Hemostasis and hemostatic agents in minimally invasive surgery. Surgery. 2007;142:S39–S45.
- Esposito P, Cappabianca P, Angileri FF, et al. Gelatin-thrombin hemostatic matrix in neurosurgical procedures: hemostasis effectiveness and economic value of clinical and surgical procedure-related benefits. J Neurosurg Sci. 2016 July 26. [Epub ahead of print]. PMID 27456032.
- Fiss I, Danne M, Stendel R. Use of gelatin-thrombin matrix hemostatic sealant in cranial neurosurgery. Neurol Med Chir (Tokyo). 2007;47:462–467.
- Gazzeri R, Galarza M, Neroni M, et al. Hemostatic matrix sealant in neurosurgery: a clinical and imaging study. Acta Neurochir (Wien). 2011;153(1):148–154.
- Gerald AG. Update on hemostasis: neurosurgery. Surgery. 2007;142:S55–S60.
- Lewis KM, Atlee HD, Mannone AJ, et al. Comparison of two gelatin and thrombin combination hemostasis in a porcine liver abrasion model. J Invest Surg. 2013;26(3):141–148.
- Mozet C, Prettin C, Dietze M, et al. Use of Floseal and effects on wound healing and pain in adults undergoing tonsillectomy: randomised comparison versus electrocautery. Eur Arch Otorhinolaryngol. 2012;269(10):2247–2254.
- Nasso G, Piancone F, Bonifazi R, et al. Prospective, randomized clinical trial of the FloSeal matrix sealant in cardiac surgery. Ann Thorac Surg. 2009;88(5):1520–1526.
- Raga F, Sanz-Cortes M, Bonilla F, et al. Reducing blood loss at myomectomy with use of a gelatin-thrombin matrix hemostatic sealant. Fertil Steril. 2009;92(1):356–360.
- Spotnitz WD. Active and mechanical hemostatic agents. Surgery. 2007;142:S34–S38.
- Oz MC, Cosgrove DM 3rd, Badduke BR, et al. Controlled clinical trial of a novel hemostatic agent in cardiac surgery. Ann Thorac Surg. 2000;69:1376–1382.
- Price JS, Tackett S, Patel V. Observational evaluation of outcomes and resource utilization from hemostatic matrices in spine surgery. J Med Econ. 2015;18:777–786.
- Renkens KL Jr., Payner TD, Leipzig TJ, et al. A multicenter, prospective, randomized trial evaluating a new hemostatic agent for spinal surgery. Spine (Phila PA 1976). 2001;26(15):1645–1650.
- Oz MC, Rondinone JF, Shargill NS. FloSeal matrix: new generation topical hemostatic sealant. J Card Surg. 2003;18:486–493.
- FLOSEAL. Hemostatic Matrix Instructions for Use. Hayward, CA: Baxter Healthcare Corporation; 2017.
- Albala DM, Lawson JH. Recent clinical and investigational applications of fibrin sealant in selected surgical specialties. J Am Coll Surg. 2005;202:685–697.
- Carless PA, Henry DA, Anthony DM. Fibrin sealant use for minimizing peri-operative allogeneic blood transfusion. Cochrane Database Syst Rev. 2003;1:CD004171.
- Tomizawa Y. Clinical benefits and risk analysis of topical hemostats: a review. J Artif Organs. 2005;8:137–142.
- Weaver FA, Hood DB, Zatina M, et al. Gelatin-thrombin-based hemostatic sealant for intraoperative bleeding in vascular surgery. Ann Vasc Surg. 2002;16(3):286–293.
- Makhija D, Rock M, Xiong Y, et al. Cost-consequence analysis of different active flowable hemostatic matrices in cardiac surgical procedures. J Med Econ. 2017;20(6):565–573.
- Finn T. Premier perspectives database: comparative effectiveness research (CER) – validated 2012. Available from: https://hcmatters.com. Accessed on 01/10/18.
- Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
- D’agostino R. Propensity score methods for bias reduction in the comparison of a treatment to a nn-randomized control group. Stat Med. 1998;17(19):2265–2281.
- Rosenbaum PR, Rubin DB. Reducing bias in observational studies using classification on the propensity score. J Amer Stat Assoc. 1984;79:516–524.
- Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41–55.
- Ikeme S, et al. Clinical and healthcare resource utilization outcomes in spine surgery: Research Poster presented at the North (NASS) Meeting, Oct 25–28, 2017, Orlando, FL, USA.
- David G, Lim S, Gunnarsson C, et al. Similar patient outcomes yet different hospital costs between flowable hemostatic agents. J Med Econ. 2015;18:735–745.
- Landi A, Gregori F, Marotta N, et al. Efficacy, security, and manageability of gelified hemostatic matrix in bleeding control during thoracic and lumbar spine surgery: floSeal versus Surgiflo. J Neurol Surg A Cent Eur Neurosurg. 2016;77:139–143.
- Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials. Circulation. 2011;123:2736–2747.
- Lewis KM, Li Q, Jones DS, et al. Development and validation of an intraoperative bleeding severity scale for use in clinical studies of hemostatic agents. Surgery. 2017;161:771–781.